Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To evaluate the pharmacokinetic difference of anlotinib hydrochloride capsule between mild/moderate liver dysfunction subjects and healthy subjects, and to provide basis for formulating the clinical drug regimen for patients with liver dysfunction.
Liver Dysfunction
Anlotinib Hydrochloride Capsule
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 30 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | To Evaluate the Phase I Pharmacokinetics of Anlotinib Hydrochloride Capsules in Liver Dysfunction Patients and Healthy Subjects |
Actual Study Start Date : | October 2022 |
Estimated Primary Completion Date : | June 2023 |
Estimated Study Completion Date : | July 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Anlotinib Hydrochloride Capsules Anlotinib hydrochloride capsules, 12mg, 1 time in total |
Drug: Anlotinib Hydrochloride Capsule |
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing, China, 40010
Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China, 410006